Rocket Pharmaceuticals, Inc. (RCKT) News

Rocket Pharmaceuticals, Inc. (RCKT): $17.93

-0.39 (-2.13%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RCKT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 402

in industry

Filter RCKT News Items

RCKT News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

RCKT News Highlights

  • For RCKT, its 30 day story count is now at 10.
  • Over the past 25 days, the trend for RCKT's stories per day has been choppy and unclear. It has oscillated between 1 and 4.
  • The most mentioned tickers in articles about RCKT are RARE and GENE.

Latest RCKT News From Around the Web

Below are the latest news stories about Rocket Pharmaceuticals Inc that investors may wish to consider to help them evaluate RCKT as an investment opportunity.

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

CRANBURY, N.J., February 24, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, 2021.

Yahoo | February 24, 2022

Hedge Fund and Insider Trading News: Leon Cooperman, Graticule Asset Management, Blackwells Capital, AQR Capital Management, Maverick Capital, Bridgewater Associates, Rocket Pharmaceuticals Inc (RCKT), and More

From Citizen Kane, chairman of the board Bernstein quips, its no trick to make a lot of money if what you want to do is make a lot of money. Downright laughable was Washington Posts catchy

Insider Monkey | February 11, 2022

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference

CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the virtual 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, Feb. 16 at 10 a.m. ET. A live audio webcast of the presentation will be available under Events in the Investors sect

Business Wire | February 10, 2022

Insider Buying: The Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) CEO & Director Just Bought 2.4% More Shares

Potential Rocket Pharmaceuticals, Inc. ( NASDAQ:RCKT ) shareholders may wish to note that the CEO & Director, Gaurav...

Yahoo | February 10, 2022

Strong Insider Buying Could Indicate a Bottom in These 2 Stocks

We saw large market declines as 2022 got started – but the real story was the increase in volatility. Especially at the beginning of February, when the market losses leveled off, daily trading was characterized by strong swings up and down. It’s a situation that puts a burden on investors, to recognize the right time to buy in for optimal profits. The key is not to try and ‘time’ it on daily trading, but to look at longer trends and future predictors. One place to find indicators toward a stock’

Yahoo | February 10, 2022

Rocket Pharmaceuticals: A Struggling Company With Long-Term Upside

Rocket Pharmaceuticals (NASDAQ: RCKT) is a biotechnology company headquartered in New York. They specialize in leading the charge in the development of first-of-their-kind genetic therapies. These gene therapies are target-specific, designed to target rare pediatric diseases. The most notable of these diseases is Fanconi anemia. Fanconi anemia is a genetic...

A Kashyap on Seeking Alpha | January 30, 2022

Rocket Pharmaceuticals (RCKT) Presents At 40th Annual J.P. Morgan Virtual Healthcare Conference

No summary available.

Seeking Alpha | January 24, 2022

Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs

CRANBURY, N.J., January 11, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today shares expected milestones for 2022, which were discussed yesterday during the Company’s virtual presentation at the 40th Annual J.P. Morgan Healthcare Conference.

Yahoo | January 11, 2022

Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

CRANBURY, N.J., January 04, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that Gaurav Shah, M.D., Chief Executive Officer, will deliver a company presentation virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, Jan. 10 at 1:30 p.m. ET.

Yahoo | January 4, 2022

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up to $21.52

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)s stock price gapped up prior to trading on Monday . The stock had previously closed at $21.52, but opened at $22.34. Rocket Pharmaceuticals shares last traded at $21.98, with a volume of 699 shares changing hands. Several research analysts have commented on RCKT shares. Zacks Investment Research lowered Rocket Pharmaceuticals from [] The post Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Gap Up to $21.52 appeared first on ETF Daily News .

ETF Daily News | December 22, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5289 seconds.